🇳🇬NigeriaWest Africa
Continental Hotels Group's Niyi Agoro recognized among Africa's Top 15 Hotelier HR Leaders
via Punch Nigeria1 min read
Niyi Agoro, Cluster Director of Human Resources for Continental Hotels Group, has been named one of Africa's Top 15 Hotelier HR Leaders for Q1 2026 by Hotelier Africa. This recognition highlights his influence in shaping workforce strategy within the hospitality sector. Continental Hotels Group stated that Agoro is a leading human capital executive redefining talent management in an industry facing digital transformation, talent mobility, and increasing guest expectations. Hotelier Africa noted that the honorees were distinguished for creating resilient talent ecosystems that support sustainable growth and competitive advantage. Agoro's approach focuses on agile organizational cultures, robust performance frameworks, and positioning talent as a core business enabler. Industry observers see this recognition as reflecting a shift where HR leadership is central to enterprise performance and competitiveness. Agoro expressed appreciation for the honor, stating it motivates him to deepen his impact in the field by aligning talent strategies with business imperatives and fostering high-performance cultures. Karl Hala, Group General Manager of Continental Hotels, said the recognition affirms the organization's commitment to excellence in human capital development, noting that under Agoro's leadership, the HR Centre has become a benchmark for talent strategy and cultural coherence.
Free daily or weekly digest of the most important stories from across 10 countries. No spam, unsubscribe any time.
This summary was AI-generated from a story originally published by Punch Nigeria.
Japan is seeking to block a takeover attempt by South Korea-based private equity fund MBK Partners of Makino Milling, a key industrial machine maker, citing national security concerns. Finance Minister Satsuki Katayama stated that the government determined it is “essential to recommend the suspension” of MBK Partners' bid to fully acquire Tokyo-based Makino Milling, described as “the world’s leading manufacturer of machine tools.” The minister noted that Makino Milling’s products are “widely used by our country’s defence equipment manufacturers,” and recognized “the risk that the investment in question can undermine our country’s security.” The recommendation was issued on Wednesday. Founded in 1937, Makino Milling provides tools for sectors including aerospace, automobile, medicine, and semiconductors. This marks reportedly only the second time a suspension edict has been issued under Japan’s foreign exchange and trade laws to prevent national security risks. MBK Partners, notified by the government that Makino Milling’s products include “sensitive goods with a particularly high potential for military use,” expressed surprise, as the takeover was slated for approval by late June. The fund has until May 1 to decide whether to comply with the suspension advisory.
Chinese startup DeepSeek has launched a new artificial intelligence model, DeepSeek-V4, featuring an ultra-long context of one million words. The company, which gained recognition last year for its cost-effective reasoning model, announced the release on WeChat and X, highlighting its "cost-effective" nature. DeepSeek-V4 is available in two versions, DeepSeek-V4-Pro and DeepSeek-V4-Flash, with the Pro version having 1.6 trillion parameters and the Flash version 284 billion parameters. The model is optimized for popular AI Agent products and, according to DeepSeek, achieves leadership in both domestic and open-source fields across agent capabilities, world knowledge, and reasoning performance. A "preview version" of the open-source model is now accessible. DeepSeek-V4-Pro is noted to significantly outperform other open-source models in world knowledge benchmarks and is only slightly behind Google's Gemini-Pro-3.1. The release comes as Meta plans staff reductions and Microsoft considers similar measures, while both invest heavily in AI. DeepSeek's previous generative AI chatbot, powered by its R1 reasoning model, challenged US dominance in the AI sector, leading to what was termed "DeepSeek shock." The company's open-source approach has led to widespread adoption of its AI tools by Chinese municipalities, healthcare institutions, and the financial sector. Chinese Premier Li Qiang recently stated that "China-made large AI models spearheaded the development of the global open-sou
The US State Department is offering up to $10 million for information leading to the identification or location of Hashim Finyan Rahim al-Saraji, also known as Abu Alaa al-Walai, the leader of the Tehran-backed Iraqi armed group Kataeb Sayyid al-Shuhada KSS. Washington designates KSS as a terrorist organization, stating the group has killed Iraqi civilians and attacked US diplomatic facilities, military bases, and personnel in Iraq and Syria. The US officials indicated that individuals providing information could be eligible for relocation and a reward. Al-Saraji is a member of the Coordination Framework, the ruling Shiite alliance with a parliamentary majority. Iran-backed groups have previously targeted the US embassy in Baghdad, its diplomatic and logistics facility at Baghdad’s airport, and oil fields operated by foreign companies. This reward follows a similar offer earlier this month for the leader of Kataeb Hezbollah, another Iraqi armed group. US media reports indicate Washington has been pressuring Baghdad to counter pro-Tehran groups by suspending cash shipments and freezing funding for security programs in Iraq.
Must ReadUS health officials have approved Otarmeni, a gene therapy developed by American biotechnology company Regeneron, to treat a rare form of hereditary hearing loss. This treatment targets severe-to-profound hearing loss caused by specific mutations in the OTOF gene, which affects approximately 50 newborns annually in the US. The OTOF gene encodes a protein essential for transmitting auditory signals from the inner ear to the brain. Regeneron plans to offer this treatment free of charge to eligible American patients, despite gene therapies typically being very expensive. Administered as a single injection into the ear, the therapy has been praised by parents of children who received it. A clinical trial involving 20 pediatric patients aged 10 months to 16 years showed that at least 80 percent experienced significant hearing improvement within a few months. Dr. Eliot Shearer, an ear, nose, and throat doctor at Boston Children’s Hospital involved in the trial, stated that the FDA's accelerated approval signifies a new era in treating genetic forms of hearing loss, making 24/7 natural hearing possible.